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9. Hypertension in children and 
adolescents
Data from randomized studies and representa-
tive population studies indicate that hypertension 
is present in 3–5% of children and adolescents aged 
0–18 years, and its incidence increases with age. In 
the OLAF and OLA studies, conducted in represen-
tative population samples, BP values above the 95th 
percentile for age and gender, calculated as the mean 
of the second and third BP measurement during 
a single visit, were noted in 6.9% of children aged 
3 years, 7.7% of children aged 6–10 years, and 6.2% 
of youths aged 10–20 years. In Polish studies studies 
(3 measurements during 3 independent visits), hy-
pertension was found in about 10% large-city ado-
lescents aged 18 years, which is consistent with the 
rate of hypertension among young adults aged 20–30 
years. Secondary hypertension is the major cause of 
hypertension in younger children. With increasing 
rates of obesity in children and adolescents, the pro-
portion of primary hypertension increases and it is 
diagnosed in about 50% of all children evaluated due 
to hypertension.
The following recommendations regarding the 
management of hypertension in children and ado-
lescents have been developed based on the previo-
usly published fourth report of the National High 
Blood Pressure Education Program Working Group 
on Children and Adolescents, paediatric guidelines 
of the ESH, ESC, the American Heart Association 
(AHA), and the American Academy of Paediatrics 
(AAP), specific guidelines of other societies, literature 
review, and expert opinion.
9.1. Recommendations regarding screening for 
hypertension
According to the ESH guidelines and the fourth 
report of the National High Blood Pressure Edu-
cation Program Working Group on Children and 
Adolescents, BP should be measured in children 
above 3 years of age at least once a year during rou-
tine health supervision visits and visits related to 
health problems. In children below 3 years of age, 
BP measurement is recommended in selected cases 
in children with identified health problems (Table 
XXVII). In Poland, according to the ordinance of 
the Minister of Health, BP should be measured 
in each child above 12 months of age during each 
physician consultation. This recommendation is not 
supported by society guidelines and epidemiolo-
gical study findings. BP measurements in younger 
children are at a high risk of failure due to lack of 
patient cooperation: the proportion of unreliable 
BP measurements is 41% in children at one year 
of age, 20% in children aged 3 years, and 9% of 
children aged 3–6 years.
9.2. Diagnosis of hypertension
9.2.1. Definitions and classification of 
hypertension in children and adolescents
According the generally accepted definition of 
hypertension in children, this diagnosis requires BP 
readings ≥ 95th percentile for age, gender, and height 
during three independent visits. Classification of hy-
pertension in children and adolescents depends on the 
method of BP measurement. Based on office measure-
ments (using the auscultatory or oscillometric method), 
the following categories are distinguished:
Normal BP — BP values below the 90th percentile 
for age, gender, and height;
•	 High normal BP (Europe) or prehypertension 
(United States) — SBP and/or DBP between 
the 90th and 95th percentile, and BP > 120/80 
mm Hg in adolescents;
•	 Hypertension — mean SBP and/or DBP values 
≥ 95th percentile for age, gender, and height in at 
least three independent measurements;
•	 White coat hypertension — office BP measure-
ments above the 95th percentile but home BP or 
ABPM values within normal limits;
•	 Grade 1 hypertension — BP values between 
the 95th percentile and 5 mm Hg above the 99th 
percentile for age, gender, and height;
•	 Grade 2 hypertension — BP values more than 
5 mm Hg above the 99th percentile for age, gen-
der, and height.
In the classification of hypertension in children 
that was adopted in both European and U.S. guide-
lines, categories of severe hypertension and hyper-
tensive urgencies and emergencies have not been 
defined. However, the following definitions of these 
conditions are used for practical reasons:
•	 Severe hypertension — BP values more than 
30 mm Hg above the 99th percentile for age, 
gender, and height;
•	 Hypertensive urgencies — impending organ 
failure related to hypertension, requiring rapid 
intervention, usually with concomitant unspe-
cific symptoms such as headache and vomiting;
•	 Hypertensive emergencies — established or 
acute organ damage related to hypertension, 
mostly with organ failure, symptoms of ence-
phalopathy, and Keith-Wagener-Barker grade 
3 and/or grade 4 retinopathy on fundoscopy.
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The classification of hypertension based on ABPM 
also includes the category of masked hypertension, 
defined as abnormal BP values in ABPM and normal 
BP values in office measurements (Table XXVIII).
9.3. Reference blood pressure values
9.3.1. Reference values for office measurements
It is recommended to use reference BP values for 
a given age, gender and height developed for specific 
BP measurement methods (auscultatory, oscillome-
tric). For BP measurements using the auscultatory 
method, the most commonly used are reference va-
lues for children aged 0–18 years, developed for the 
population of the United States, Canada, Mexico, 
and Great Britain and published in the fourth report 
of the National High Blood Pressure Education Pro-
gram Working Group on Children and Adolescents. 
For oscillometric (automated) BP measurements, 
Table XXVII. Blood pressure measurements in children and adolescents — indications and technique.
BP should be measured in all children aged > 3 years at least once a year and during any routine physician examination.
Technique and indications:
•	BP measurement is more reliable if the child has not eaten a meal within 30 minutes before the measurement, has not received medications that 
might affect BP, and has been resting in a sitting position with its back supported in a quiet environment for 5–10 minutes before the measure-
ment.
•	During	the	initial	consultation,	BP	should	be	measured	on	all	four	limbs.	During	the	first	year	of	life	and	until	the	child	assumes	the	upright	 
position,	BP	readings	in	the	lower	limbs	are	lower	than	in	the	upper	limbs.	During	the	second	year	of	life	in	a	child	who	stands/walks,	BP	readings	
in	the	lower	limbs	are	higher	by	about	20	mm	Hg,	and	at	a	later	age	they	are	higher	by	about	30–40	mm	Hg.
•	Subsequent	measurements	should	be	performed	on	the	right	arm	that	is	fully	exposed,	abducted	and	supported	at	the	level	of	the	heart.
•	The	cuff	should	encircle	the	full	circumference	of	the	arm	and	cover	at	least	two	thirds	of	its	length.	The	inflatable	bladder	should	encircle	at	least	
80%	of	the	arm	circumference,	including	the	whole	medial	aspect	of	the	arm.	A	measurement	performed	using	a	cuff	that	is	too	narrow	may	 
overestimate	BP	by	as	much	as	30%,	and	underestimate	BP	if	the	cuff	is	too	wide.
•	In	infants,	the	body	position	has	no	significant	effect	on	BP	values.	During	sleep,	SBP	values	in	infants	are	lower	by	5–7	mm	Hg.
•	As	readings	obtained	during	the	first	measurement	are	usually	overestimated,	in	such	cases	—	BP	should		be	measured	2–3	times	on	one	 
occasion.
•	BP readings above the 90th	percentile	by	the	oscillometric	method	require	verification	by	the	auscultatory	method.
•	If the BP difference between the upper limbs is ≥	5	mm	Hg,	this	fact	should	be	noted	in	the	medical	record.
In younger children (< 3 years), BP should be measured in the following situations:
•	perinatal	morbidity	(prematurity,	low	birth	weight,	perinatal	intensive	therapy)
•	congenital anomalies
•	recurrent	urinary	tract	infections,	other	renal	and/or	urinary	tract	disease
•	cancer
•	solid organ or bone marrow transplantation
•	use of drugs affecting BP
•	symptoms	and	conditions	associated	with	hypertension	(neurofibromatosis,	tuberous	sclerosis,	others),	intracranial	pressure	rise
BP, blood pressure
Table XXVIII.	Blood	pressure	classification	in	children	based	on	ambulatory	blood	pressure	monitoring	(based	on	Flynn	et 
al.,	Hypertension	2014)
Category Office BP Mean SBP and/or DBP by ABPM SBP and/or DBP load
Normal BP < 90th percentile < 95th percentile <	25%
White	coat	hypertension ≥ 95th percentile < 95th percentile <	25%
Masked	hypertension < 95th percentile ≥ 95th percentile <	25%
High	normal	BP ≥ 90th	percentile	and/or	120/80 < 95th percentile 25–50%
Ambulatory	hypertension ≥ 95th percentile ≥ 95th percentile 25–50%
Severe	ambulatory	hypertension ≥ 95th percentile ≥ 95th percentile > 50%
ABPM,	ambulatory	blood	pressure	monitoring;	BP,	blood	pressure;	DBP,	diastolic	blood	pressure;	SBP,	systolic	blood	pressure
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reference values developed for the Polish population 
of children aged 3–18 years (www.olaf.czd.pl) are 
recommended.
9.3.2. Home blood pressure measurements
In children with the diagnosis of hypertension, 
home BP measurements using a validated oscillo-
metric device are recommended. Use of the refe-
rence values developed by Stergiou et al. for children 
and adolescents aged 6–18 years is recommended 
(Table XXIX). No reference BP values were devel-
oped for HBPM in younger children. Evaluation 
based on BP measurements twice daily during at 
least 3 days is considered reliable, and the optimal 
approach involves morning and evening BP mea-
surements performed during 7 subsequent days. 
Adequate home BP measurements are considered 
a reliable indicator of the effectiveness of antihyper-
tensive therapy.
9.3.3. Ambulatory blood pressure measurement
Ambulatory BP measurement using a validated 
oscillometric device is recommended in all children 
above 5 years of age in whom hypertension was diag-
nosed based on office BP measurements. Use of the 
reference BP values for ABPM developed by Wühl 
et al. and adopted in the 2014 AHA guidelines is 
recommended. Routine repeated ABPM is recom-
mended to evaluate treatment effects.
9.3.4. Interpretation issues
When interpreting BP measurements, age, gen-
der, and height of the patient should be taken into 
consideration. Significant issues have been raised 
for neonates (see “Neonatal hypertension” below), 
children in the first year of life, and adolescents, as 
well as interpretation of oscillometric measurements 
including ABPM. In neonates and children in the 
first year of life in whom BP was measured, evalua-
Table XXIX.	Reference	home	blood	pressure	values	(95th 
percentile)	in	boys	and	girls	(based	on	Stergiou	et al., Am. 
J.	Hypertens.	2008)
Height Girls Boys
120−129 119/74 119/76
130−139 120/76 121/77
140−149 122/77 125/77
150−159 123/77 126/78
160−169 124/78 128/78
170−179 125/79 132/78
180−189 128/80 134/79
tion of SBP only is recommended. Of note, the 95th 
percentile SBP values for girls aged 13–18 years are 
much lower compared to those for boys, and at the 
age of 18 years, the 95th percentile values for both 
SBP and DBP in girls are 5–10 mm Hg lower than 
140/90 mm Hg. The latter values correspond to 99th 
percentile in girls aged 18 years.
As most currently used ABPM devices are based 
on the oscillometric method, it should be empha-
sized that with this method, the mean arterial pres-
sure (MAP) is directly evaluated, and SBP and DBP 
values are calculated using appropriate algorithms. In 
addition, results of some controlled paediatric studies 
(e.g., the ESCAPE study) and therapeutic recom-
mendations (see below) are based on the analysis 
of MAP values. Another interpretation issue related 
to ABPM is the fact that using this method, higher 
BP values comparted to office measurements are ob-
tained in children below 10 years of age and those 
with the height below 120 cm. Due to lacking refer-
ence values and the above mentioned interpretation 
issues, routine use of ABPM is not recommended in 
children below 5 years of age.
9.4. Methods to evaluate target organ damage
Basic approaches to evaluate the severity of hy-
pertensive target organ damage in children include:
•	 evaluation of left ventricular mass, systolic func-
tion, and diastolic function by echocardiography;
•	 ECG;
•	 fundoscopy;
•	 evaluation of renal function.
9.4.1. Evaluation of left ventricular mass
Left ventricular mass (LVM) is a major criterion 
of target organ damage in hypertension. Echocar-
diography is the standard method to diagnose left 
ventricular hypertrophy, and ECG is only an ad-
ditional diagnostic tool due to its low specificity 
and the need for age-specific interpretation. The 
most commonly used approach to evaluate LVM 
is based on the recommendations of the American 
Society of Echocardiography and uses the Deveraux 
formula. As LVM depends on height, it is recom-
mended to calculate LVM indexed for height in 
meters to the power of 2.7 according to the formula 
suggested by DeSimone. Published reference values 
and percentiles of the LVM index calculated using 
this formula allow using this parameter in children 
over 1 year of age. A limitation of indexing LVM for 
height is the possibility to overdiagnose left ventri-
cular hypertrophy in obese children in comparison 
to indexing for fat-free body weight. Nevertheless, 
it is currently the most commonly used and recom-
arterial hypertension 2015, vol. 19, no. 3
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Table XXXI.	Reference	common	carotid	artery	intima-me-
dia	thickness	values	(50th and 95th	percentile)	in	millimetres	
(based	on	Doyon	et al.,	Hypertension	2013)	(values	roun-
ded	to	the	nearest	0.01	mm;	reprinted	with	permission	
from	Standardy	Medyczne)
50th percentile 95th percentile
Age 
(years)
Boys Girls Boys Girls
6 0.37 0.36 0.44 0.43
7 0.37 0.37 0.44 0.43
8 0.37 0.37 0.44 0.44
9 0.37 0.37 0.45 0.44
10 0.38 0.37 0.45 0.44
11 0.38 0.38 0.45 0.44
12 0.38 0.38 0.46 0.44
13 0.38 0.38 0.46 0.45
14 0.39 0.38 0.47 0.46
15 0.39 0.38 0.47 0.46
16 0.4 0.39 0.48 0.46
17 0.4 0.39 0.48 0.46
18 0.40 0.39 0.48 0.47
mended approach to evaluate LVM in children and 
adolescents that allows not only comparisons of 
echocardiographic findings in children of varying 
age but also comparing paediatric data with the 
results obtained in adults. The principles of evalu-
ating left ventricular systolic and diastolic function 
are the same as in adults.
Definitions:
 —  left ventricular hypertrophy — LVM ≥ 95th per-
centile for age and gender (Table XXX)
 —  severe ventricular hypertrophy — LVM index 
≥ 51 g/m2.7*
9.4.2. Fundoscopy
The principles of fundoscopic examination in 
children do not differ from those in adults. The 
Keith-Wagener-Barker classification is commonly 
used in clinical practice. A simplified classification 
includes 2 types of changes, benign and malignant. 
Benign changes are Keith-Wagener-Barker grade 1 
and/or grade 2 lesions, and malignant changes are 
grade 3 and/or grade 4 lesions. The simplified clas-
sification allows initial patient selection for more or 
less intensive treatment.
9.4.3. Evaluation of renal damage
Routine methods to evaluate renal function in-
clude glomerular filtration rate (GFR) estimation 
using the Schwartz formula and/or serum cystatine C 
level measurements. Albuminuria is an indicator of 
hyperfiltration and/or microvascular damage. There 
are no commonly accepted reference values for al-
buminuria in children, and adult cut-off values are 
used in practice, with albuminuria above 30 mg/24 h 
corresponding to the 95th percentile values.
Hyperuricaemia is considered an abnormality 
specific for hypertension. However, it is not clear 
whether an increased uric acid level is a primary 
phenomenon or occurs secondarily to subclinical 
renal damage.
9.4.4. Non-obligatory additional tests to evaluate 
the extent of target organ damage in children and 
adolescents
Non-obligatory additional tests to evaluate the 
extent of target organ damage in children and ado-
lescents include:
•	 evaluation of large artery damage (measurement 
of the intima-media thickness [IMT]);
•	 measurement of the pulse wave velocity (PWV).
During the last decade, multiple reports have been 
published that support using IMT and PWV mea-
surements to evaluate target organ damage, and ref-
erence IMT and PWV values for children and ado-
lescents aged 6–20 years have been reported (Tables 
XXXI and XXXII).
*In	observational	studies	in	adults,	LVM	index	≥	51	g/m2.7	(approximately	corresponding	to	the	99th	percentile	of	LVM	in	the	paediatric	population)	has	been	associated	with	a	4-fold	increase	in	the	
risk	of	a	cardiovascular	event	over	5	years
Table XXX.	Reference	left	ventricular	mass	index	values	
(95th	percentile)	in	children	(based	on	Khoury	et al., J. Am. 
Soc.	Echocardiogr.	2009)
Age 95th percentile LVMI [g/m2.7]
Boys Girls
<	6	months 80.1 85.6
≥	6	months	to	≤	2	years 68.6 57.1
2	years	to	≤	4	years 52.4 55.3
4	years	to	≤	6	years 48.1 44.3
6	years	to	≤	8	years 44.6 43.5
8	years	to	≤	10	years 41 36
10	years	to	≤	12	years 38.2 35.7
12	years	to	≤	14	years 41.4 38.2
14	years	to	≤	16	years 40.5 36.9
≤	16	years 39.4 40
LVMI,	left	ventricular	mass	index
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Table XXXII.	Reference	pulse	wave	velocity	values	(95th	and	97th	percentile)	evaluated	by	tonometry	(PulsePen;	based	on	
Reusz	et al.,	Hypertension	2010)	and	the	oscillometric	method	(Vicorder;	based	on	Fischer	et al.,	J	Hypertens	2012;	reprin-
ted	with	permission	from	Standardy	Medyczne)
Age (years) PulsePen (tonometry) Vicorder (oscillometric method)
Boys  
(95th percentile, m/s)
Girls  
(95th percentile, m/s)
Boys  
(97th percentile, m/s)
Girls  
(97th percentile, m/s)
7 5.4 5.2 4.8 4.8
8 5.5 5.4 5.0 5.0
9 5.5 5.5 5.1 5.1
10 5.6 5.6 5.2 5.3
11 5.8 5.8 5.4 5.4
12 5.9 5.9 5.5 5.5
13 6.1 6.0 5.7 5.6
14 6.3 6.0 5.8 5.7
15 6.5 6.2 6.0 5.7
16 6.7 6.3 6.2 5.7
17 6.9 6.5 6.3 5.6
18 7.1 6.7
19 7.3 6.9
9.5. Principles of the differential diagnosis of 
hypertension in children and adolescents
Differential diagnosis of hypertension in children 
includes three steps (Table XXXIII). The extent of 
diagnostic investigations depends on the severity of 
hypertension, patient’s age, and concomitant condi-
tions. Indications for more extensive investigations 
that include diagnostic steps 1 and 2 are younger 
patient’s age (before puberty; an arbitrarily chosen 
age threshold is 12 years) and/or grade 2 hyperten-
sion and/or presence of target organ damage and 
concomitant chronic conditions. Diagnostic step 1 
includes confirmation of the diagnosis of hyperten-
sion, exclusion of white coat hypertension, grading 
the severity of hypertension, evaluation of target or-
gan damage, and basic laboratory tests to exclude 
secondary hypertension. Diagnostic step 2 includes 
tests that require hospital admission and is generally 
appropriate in children with grade 2 hypertension 
and younger children with hypertension. Diagnostic 
step 3 includes highly specialized tests reserved for 
patients in whom the diagnosis has not been estab-
lished despite completed step 1 and 2 investigations 
or hypertension is resistant to treatment.
The diagnosis of hypertension in children and 
adolescents should by confirmed by ABPM. Due to 
lacking reference values for younger children and the 
possibility of false positive diagnoses, only children 
above 5 years of age and/or above 120 cm in height 
should be routinely referred for ABPM. In younger 
children, the diagnosis of hypertension is based on 
office measurements.
In most children with hypertension, an immediate 
institution of antihypertensive therapy is not neces-
sary, which usually allows complete diagnostic investi-
gations before the treatment is started. Indications for 
initiating antihypertensive therapy before completion 
of the differential diagnosis include high BP values 
(grade 2 hypertension with clinical symptoms) and/ 
/or advanced target organ damage and/or symptomatic 
hypertension (hypertensive urgencies and emergen-
cies). Except for hypertensive urgencies and emergen-
cies, if drug treatment is necessary before completion 
of the diagnostic tests, long-acting dihydropyridine 
calcium antagonists are preferred as this drug class has 
the least effect on laboratory test findings.
9.6. General approach to the treatment of 
hypertension
General approach to and indications for the treat-
ment of hypertension in children and adolescents are 
based on evaluation of the severity of hypertension, 
its nature (primary versus secondary), and concomi-
tant conditions and target organ damage. Treatment 
monitoring and modifications based on ABPM are 
recommended (Figure 13). Antihypertensive drug 
treatment and its success rates depend on the aetio-
logy of hypertension.
arterial hypertension 2015, vol. 19, no. 3
108 www.nt.viamedica.pl
9.6.1. Primary hypertension
Primary hypertension is the major cause of hyper-
tension in children above 12 years of age, accounting 
for about 50% of all cases of hypertension in the 
developmental period. The predominant interme - 
diate phenotype of primary hypertension is abnormal 
body composition with visceral obesity, abnormal 
muscle-to-adipose tissue proportion, and metabolic 
disturbances typical for metabolic syndrome (Table 
XXXIV). The risk of target organ damage is related 
to the degree of metabolic abnormalities and the 
amount of visceral fat as evaluated by waist circum-
ference.
9.6.1.1. Management of primary hypertension
Non-drug therapy including both dietary modifi-
cations and physical activity is of major importance 
in the management of primary hypertension. Dietary 
modifications are based on the principles of healthy 
eating and require limiting, and in practice essential-
ly eliminating adding salt to foods and simple sugar 
consumption. Obese children with hypertension re-
quire a dietitian consultation and management as in 
simple obesity.
Exercise is of major importance in both prevention 
of essential hypertension and non-drug treatment 
of children with essential hypertension. Prospective 
Table XXXIII.	Diagnostic	steps	in	children	with	hypertension	(reprinted	with	permission	from	Standardy	Medyczne	2008)
Investigations Comments
Step 1 •	complete blood count, creatinine, sodium, potassium, chloride, 
calcium,	bicarbonate,	total	cholesterol,	triglycerides,	HDL	and	LDL	
cholesterol, uric acid, glucose
•	urinalysis
•	daily	albumin	excretion	or	albumin/creatinine	ratio	in	a	spot	urine	
sample
•	fundoscopy
•	kidney	and	renal	artery	Doppler	ultrasound
•	ECG
•	echocardiography	with	evaluation	of	LVM	and	the	aortic	arch
•	IMT measurement
•	transfontanellar ultrasound in neonates
•	ABPM	in	children	>	5	years
Step 1 investigations should be performed in all patients with 
the	diagnosis	of	hypertension
IMT measurement is optional
ABPM	is	currently	widely	available;	evaluation	in	children	 
<	6	years	has	not	been	validated
Step	2 •	glycaemia,	oral	glucose	tolerance	test,	insulinaemia	in	patients	with	
BMI >85th percentile
•	urinary	catecholamines	in	younger	children	and	all	patients	with	
grade	2	hypertension
•	plasma	renin	activity/renin	level	and	aldosterone	level	in	younger	
children	and	all	patients	with	grade	2	hypertension
•	urinary	steroid	profile	or	urinary	17-keto-	and	17-hydroxysteroids	in	
younger	children	and	all	patients	with	grade	2	hypertension
•	thyroid	hormones,	vitamin	D3	metabolites
•	renal	scintigraphy	(captopril	test)	in	younger	children	and	all	patients	
with	grade	2	hypertension
Oral	glucose	tolerance	test	is	recommended	as	mandatory	in	
patients with BMI > 85th percentile
Fasting	insulin	allows	calculation	of	HOMA-IR,	and	insulin	in	the	
fasting	conditions	and	at	120	minutes	after	glucose	administra-
tion	allows	evaluation	of	the	insulin	sensitivity	index
Multiple	measurements	during	a	240-minute	test	allow	calcu-
lation of areas under the glucose and insulin curves and are 
optional
Urinary	steroid	profile	is	currently	recommended	over	previously	
used	urinary	17-keto-	and	17-hydroxysteroids
Measurements	of	thyroid	hormones	and	vitamin	D3	metabolites	
in	patients	with	a	suspicion	of	specific	pathologies
Dynamic	scintigraphy	is	recommended	to	evaluate	renal	per-
fusion,	urine	excretion,	relative	renal	function,	and	to	estimate	
scarring	(static	DMSA	scintigraphy	is	more	sensitive	in	detec-
ting	scarring	but	does	not	allow	evaluation	of	renal	perfusion)
Step 3 •	non-invasive	and	invasive	renal	artery	imaging	(CTA,	MRA,	invasive	
angiography)
•	imaging	to	detect	adrenal	lesions/paraganglioma
•	non-invasive	imaging	of	other	vascular	beds	(visceral	arteries,	intra-
cranial	arteries)
•	molecular testing
Step 3 investigations are performed in patients in whom the 
diagnosis has not been established despite completed step 1 
and	2	investigations	and/or	treatment	is	unsuccessful
ABPM,	ambulatory	blood	pressure	monitoring;	BMI,	body	mass	index;	CTA,	computed	tomography	angiography;	DMSA,	dimercaptosuccinic	acid;	ECG,	electrocardiogram;	HDL,	high-density	lipoprotein;	
HOMA-IR,	homeostatic	model	assessment-insulin	resistance;	IMT,	intima-media	thickness;	LDL,	low-density	lipoprotein;	LVM,	left	ventricular	mass;	MRA,	magnetic	resonance	angiography
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Figure 13. Treatment	of	hypertension	in	adolescents	(modifications	based	on	European	Society	of	Hypertension,	J.	Hypertens.	2009;	reprinted	
with	permission	from	Standardy	Medyczne)
Tabela XXXIV. Definitions	of	metabolic	syndrome	(based	on	Zimmet	et al.,	Paediatric	Diabetes	2007)
Age Criteria
<	10	years Metabolic	syndrome	should	not	be	diagnosed.	Extended	diagnostic	investigations	are	indicated	in	risk	groups.
10–15	years	 
(<	16	years)
Waist circumference ≥ 90th percentile or ≥	cut-off	point	for	adult	patients	+	2	or	more	from	the	following	criteria:
—	serum	triglycerides	≥	150	mg/dL
—	serum	HDL	cholesterol	<	40	mg/dL
— SBP ≥130	mm	Hg	and/or	DBP	≥	85	mm	Hg
— fasting blood glucose ≥	100	mg/dL	or	type	2	diabetes
>	16	years Criteria as in adults:
— waist circumference ≥	94	cm	in	boys	and	≥ 80 cm in girls
—	serum	triglycerides	≥	150	mg/dL
—	serum	HDL	cholesterol	<	40	mg/dL	in	boys	and	<	50	mg/dL	in	girls
— SBP ≥	130	mm	Hg	and/or	DBP	≥	85	mm	Hg	or	antihypertensive	drug	treatment
— fasting blood glucose ≥	100	mg/dL	or	type	2	diabetes
DBP,	diastolic	blood	pressure;	HDL,	high-density	lipoprotein;	SBP,	systolic	blood	pressure
studies showed a beneficial effect of moderate-in-
tensity regular exercise on BP lowering, increased 
flow-mediated endothelium-dependent vessel dila-
tation, and reduction of arterial stiffness in obese 
children. Daily high- to moderate-intensity exercise 
for 60 to 90 minutes is recommended.
9.6.1.2. Participation in sports by children  
and adolescents with essential hypertension
Major temporary contraindications to participa-
tion in sports include grade 2 hypertension until BP 
is controlled, and/or identification of severe target or-
gan damage. Of note, however, no data indicate that 
even intensive dynamic exercise is associated with 
a significant risk. Similarly, no data indicate an asso-
ciation of static (isometric) exercise with an increased 
risk of complications. However, due to a significant 
increase in DBP, experts and societies (e.g., AAP) do 
not recommend class IIIA-C exercise (class IIIA — 
moderate physical activity: gymnastics, martial arts, 
sailing, rock-climbing, water skiing, weightlifting, 
windsurfing; class IIIB — moderately intense physi-
cal activity: body-building, alpine skiing, skateboard-
ing, snowboarding, wrestling; class IIIC — intense 
physical activity: boxing, canoeing/rowing, cycling, 
triathlon and other multisport competitions) until 
BP is controlled in patients with grade 2 hyperten-
sion. Participation in sports is not contraindicated in 
patients with grade 1 hypertension.
Non-drug therapy as the major approach to the 
treatment of grade 1 hypertension is used for 3–12 
months. Drug therapy should be considered in chil-
dren with grade 1 hypertension in whom BP was not 
adequately lowered despite 6–12 months of non- 
-drug therapy. Drug therapy is indicated in children 
with grade 2 hypertension and/or target organ da-
mage. Due to concomitant metabolic disturbances, 
beta-blockers and diuretics are not recommended as 
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first- and second-line drugs, and the preferred drug 
classes are ACEI, ARB, and dihydropyridine calcium 
antagonists. In post-pubertal women who do not use 
contraception, new generation beta-blockers with 
vasodilatatory properties may be used, as these drugs 
do not induce adverse metabolic effects. Due to the 
fact that the risk of target organ damage is associated 
with metabolic disturbances and visceral obesity, it 
is recommended to include regular anthropometric 
measurements (waist circumference) in addition to 
evaluation of BP values and target organ damage 
when monitoring treatment effects.
9.7. Hypertension in chronic kidney disease
In the paediatric population, hypertension se-
condary to chronic kidney disease is the major cause 
of hypertension in younger children, and the major 
cause of severe hypertension with target organ dam-
age at all ages. Hypertension is present in more than 
54% of children with chronic kidney disease. Poorly 
controlled hypertension is a cause of cardiovascular 
deaths during renal replacement therapy. In addition, 
hypertension is a major risk factor for progression of 
chronic kidney disease. Goals of hypertension treat-
ment in children with chronic kidney disease include 
both reduction of the risk of future cardiovascular 
events and delaying progression of chronic kidney 
disease. According to the ESC and Kidney Disease 
Improving Global Outcomes (KDIGO) guidelines, 
the BP threshold for initiating antihypertensive the-
rapy is the 90th percentile for gender and age. Target 
BP values depend on the severity of proteinuria. 
These recommendations were based on the result 
of the ESCAPE study that showed that in children 
with proteinuria, the risk of chronic kidney disease 
progression is reduced by 35% with intensification 
of antihypertensive therapy compared to the con-
ventional BP target. It is recommended to monitor 
antihypertensive treatment by ABPM, and treatment 
effectiveness should be evaluated bases on the mean 
24-hour MAP. Reduction of the mean 24-hour MAP 
below the 90th percentile is recommended in children 
with chronic kidney disease without proteinuria or 
with proteinuria below 0.5 g per day, and below the 
50% percentile in children with proteinuria above 
0.5 g per day.
First-line antihypertensive drug classes in children 
with chronic kidney disease are RAAS inhibitors: 
ACEI and ARB. This is based on the pathomecha-
nism of hypertension in chronic kidney disease and 
the published results of clinical trials and observa-
tional studies in children. Prospective multicentre 
studies showed the efficacy and safety of ACEI as 
antihypertensive and renoprotective drugs (rami-
pril, enalapril), and similar data were obtained for 
ARB (losartan) in single-centre studies. In addition, 
observational studies showed better BP control in 
children treated with RAAS inhibitors compared to 
other antihypertensive drug classes. These drugs are 
not recommended in patients with a very low GFR 
(< 15–20 mL/min/1.73 m2) due to a risk of signifi-
cant renal function worsening and/or hyperkalaemia. 
Dual therapy with ACEI and ARB may result in 
an additional BP-lowering effect and a reduction 
of proteinuria. However, such treatment is current-
ly not recommended if additional indications are 
not present (antiproteinuric effect) due to concerns 
regarding the safety of such combined treatment. 
Renin inhibitors were tested in clinical studies in 
children but their renoprotective effect was not eva-
luated and these drugs continue not to be licensed 
for use in children.
Achieving target BP in patients with chronic kid-
ney disease usually requires multiple antihypertensive 
drugs. Individualization of further drug treatment 
depending on the clinical scenario is recommended 
in children. Beta-blockers are the recommended se-
cond-line drugs in children with chronic kidney dis-
ease due to their additional effect on the RAAS and 
a reduction of proteinuria. Diuretics are recommended 
for fluid retention which is usually seen in children 
with GFR below 40 mL/min/1.73 m2. In children 
with large proteinuria or low GFR, often the diuretic 
dose has to be increased for an adequate therapeutic 
effect. Thiazide/thiazide-like diuretics retain their ef-
fectiveness only in patients with GFR above 30–40 
mL/min/1.73 m2. Dihydropyridine calcium antago-
nists, previously used as first-line drugs in children 
with chronic kidney disease, are currently used as 
further choice drugs due to the fact that they increase 
proteinuria. This negative effect is absent or reduced 
in combination with RAAS inhibitors.
9.8. Renovascular hypertension
Renovascular hypertension is among the major 
causes of severe hypertension in children and ado-
lescents. The main cause of renovascular hyperten-
sion in this age group is FMD, but in 20–40% of 
cases renovascular hypertension is a complication 
of other conditions (syndromic renovascular hy-
pertension), including neurofibromatosis type 1 
(>15%). Renovascular hypertension may also be 
caused by a congenital or acquired (e.g., transplant 
renal artery stenosis) stenosis of the main renal 
artery or additional renal arteries and/or segmental 
branches.
 2015 Guidelines for the Management of Hypertension
111www.nt.viamedica.pl
Figure 14. Diagnosis	and	treatment	in	children	with	renovascular	hypertension
CNS,	central	nervous	system;	CTA,	computed	tomography	angiography;	MRA,	magnetic	resonance	angiography;	PTRA,	percutaneous	transluminal	renal	angioplasty
9.8.1. Investigations for and the diagnosis of 
renovascular hypertension
The diagnosis of renovascular hypertension is 
based on a finding of a hemodynamically significant 
stenosis of one or both renal arteries (Figure 14). In-
vasive angiography, often with selective renal artery 
catheterization, continues to be a reference method 
but should be performed only if percutaneous treat-
ment is planned based on the results of non-invasive 
imaging. Routine evaluation of renal vein renin ac-
tivity or level is not recommended. This test may be 
performed in case of diagnostic uncertainties.
9.8.2. Treatment of renovascular hypertension
The ultimate and causative therapy of renovas-
cular hypertension is an interventional treatment 
that eliminates the underlying cause of hyperten-
sion. Although drug treatment allows at least partial 
BP control, it does not cure the patient. In patients 
with Takayasu disease, immunosuppressive treatment 
should be considered causative therapy. 
9.8.2.1. Drug treatment of renovascular hypertension
The approach to drug treatment depends on whether 
unilateral or bilateral RAS is present (Table XXXV).
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Table XXXV.	Drug	treatment	of	renovascular	hypertension
Unilateral renal artery stenosis Bilateral renal artery stenosis
ACEI/ARB Diuretics
Dihydropyridine	calcium	antagonists Dihydropyridine	calcium	antagonists
Beta-blockers Beta-blockers
Alpha-blockers Alpha-blockers
Centrally	acting	imidazoline	agonists Centrally	acting	imidazoline	agonists
ACEI,	angiotensin-converting	enzyme	inhibitors;	ARB,	angiotensin	receptor	blockers
9.8.2.2. Interventional treatment of renovascular hypertension
Interventional treatment of renovascular hyperten-
sion includes percutaneous transluminal renal angio-
plasty (PTRA) and surgical revascularization. PTRA 
may be successfully undertaken by balloon angioplasty 
with or without stenting. PTRA is the initial step of 
the interventional treatment and it should it be at-
tempted during invasive renal angiography. Complica-
tions of PTRA include mechanical vessel wall damage 
with formation of a pseudoaneurysm, thrombosis, 
arterial spasm, arterial wall laceration with bleeding, 
and entrapment of a balloon catheter within the vessel 
lumen. Some complications may require immediate 
surgical treatment, and thus both invasive renal an-
giography and PTRA should be performed in expe-
rienced paediatric centres with vascular surgical team 
backup. Local administration of an arterial smooth 
muscle relaxant should be always possible throughout 
the PTRA procedure. Drugs administered locally to 
relieve arterial spasm during PTRA include nifedipine, 
nitroglycerin, and sodium nitroprusside. According 
to experts’ recommendations, prophylactic doses of 
low-molecular-weight heparin should be given for 1–7 
days after the procedure in all cases of renal artery 
catheterization with PTRA, followed by administra-
tion of ASA at 1 mg/kg/day for 3–6 months.
Experience with stenting in renovascular hyperten-
sion in children and adolescents is relatively limited. 
Due to ongoing growth, stents mounted on balloon 
catheters that can be redilated later are recommended. 
If it is possible to implant a stent with a diameter cor-
responding to the size of the renal artery in an adult 
person, a self-expanding stent can be used.
9.8.2.3. Surgical treatment of renovascular hypertension
Two major approaches to the surgical treatment of 
renovascular hypertension are revascularization and 
nephrectomy. Surgical revascularization is indicated 
if drug therapy and PTRA were unsuccessful, and 
nephrectomy is indicated for unilateral RAS with 
severely impaired function of the ischemic kidney. 
Nephrectomy is considered appropriate if the ische-
mic kidney is reduced in size and its relative function 
has decreased to below 10–15%. In children and 
adolescents in whom renovascular hypertension is as-
sociated with an involvement of visceral vessels and/ 
/or midaortic syndrome, the therapeutic approach 
must be planned individually and mostly commonly 
involves staged procedures, taking into consideration 
their possible extent, type and sequence, including 
renal revascularization.
Major surgical techniques used for renal revas-
cularization in adolescents include repair using 
a prosthetic or autologous patch, and kidney auto-
transplantation following excision of the stenosed 
arterial segment.
9.9. Hypertension in children after surgical 
treatment of coarctation of the aorta
Hypertension is an invariable and major symptom 
of congenital coarctation of the aorta. Following in-
terventional treatment that resulted in a correction 
of the anatomical stenosis, hypertension persists or 
develops after a period of normotension in about 
32.5% (25–68%) of patients. In a large proportion 
of patient, exercise-induced hypertension may be 
diagnosed based on an exercise test.
9.9.1. Treatment of hypertension in children after 
surgical treatment of coarctation of the aorta
Paediatric studies showed efficacy of ACEI (rami-
pril), ARB (candesartan), and metoprolol. AHA re-
commends ARB or ACEI and beta-blockers as first-
line drugs. Routine annual ABPM and an exercise 
test every 2 years are recommended by the experts. 
Abnormal results of these tests are an indication 
for drug therapy and possible diagnostic investiga-
tions for recoarctation. According to the 2010 ESC 
guidelines, aortic imaging by MRI is recommended 
every two years in young adults who were treated for 
coarctation of the aorta.
9.10. Hypertension in children with type 1 
diabetes
Hypertension is present in 5–25% of children 
with type 1 diabetes, and high normal BP is present 
 2015 Guidelines for the Management of Hypertension
113www.nt.viamedica.pl
Table XXXVI.	Treatment	of	hypertension	in	children	with	diabetes	type	1
Threshold values Treatment
BP > 90th percentile for age, gender, and height Lifestyle	changes*
BP > 90th	percentile	for	age,	gender,	and	height	despite	lifestyle	changes +	ACEI/ARB
BP > 95th	percentile	for	age,	gender,	and	heightLifestyle	changes*	 +	ACEI/ARB
*Body	weight	reduction	to	normal	values	(body	mass	index	<	85th	percentile)	and	physical	activity	>1	hour	per	day 
ACEI,	angiotensin-converting	enzyme	inhibitors;	ARB,	angiotensin	receptor	blockers;	BP,	blood	pressure
in 30–40% of these children. Hypertension is much 
more prevalent in children with type 2 diabetes (30–
–50%). Diabetic patients are also characterized by 
an abnormal BP pattern, including non-dipping and 
rapid and significant morning BP surge.
Elevated BP is associated with significantly worse 
outcomes in patients with diabetes, as it is an impor-
tant risk factor for micro- and macrovascular compli-
cations and premature mortality in this population. 
An abnormal BP pattern precedes development of 
diabetic nephropathy.
9.10.1. Indications for and approach to screening
According to AHA and AAP statements, BP mea-
surement during each visit in a diabetic clinic in all 
children above 7 years (minimum 3 times a year) is 
recommended. In younger children, BP should be 
measured at least twice a year.
Investigations for secondary hypertension using 
the approach discussed above should be performed 
in patients with grade 2 hypertension, particularly if 
it is found during the first years after the diagnosis of 
diabetes and in all diabetic children below 10 years 
of age.
9.10.2. Treatment
The target BP is below the 90th percentile for age, 
gender, and height, and below 130/80 mm Hg in 
adolescents. Non-drug therapy including increased 
physical activity and dietary modifications is the ba-
sic approach to treatment. For drug therapy, the rec-
ommended antihypertensive drug classes are ACEI 
or, in case of ACEI intolerance, ARB. Drug treat-
ment should be monitored by HBPM and ABPM, 
and the nocturnal BP fall should be taken into con-
sideration (Table XXXVI).
9.11. Monogenic hypertension
The diagnosis of monogenic hypertension is based 
on the finding of a typical intermediate phenotype, 
which is often possible already during step 1 and 
2 investigations. In some cases, a family history of 
hypertension associated with a typical phenotype or 
resistant to treatment may be ascertained (Figure 15). 
Autosomal dominant brachydactyly with hyperten-
sion has not been included in the presented scheme 
due to an unspecific biochemical phenotype (normal 
or mildly elevated plasma renin activity, normal al-
dosterone level) and a characteristic clinical pheno-
type. The diagnosis of a specific form of secondary 
hypertension allows successful treatment directed at 
its underlying cause.
9.12. Neonatal hypertension
Despite multiple data on normal BP values in 
neonates depending on specific measurement tech-
niques, the definition of hypertension is still based 
on the percentile values reported in the 1987 Report 
of the Second Task Force on Blood Pressure Control 
in Children and derived from BP measurements us-
ing a mercury sphygmomanometer (Table XXXVII). 
According to the 1987 Report of the Second Task Force, 
hypertension may be diagnosed in neonates when 
SBP values above the 95th percentile for chronologi-
cal age are found on three occasions. Table XXXVIII 
shows a compilation of previous reference BP values 
by Dionne at al. that summarizes the 95th and 99th SBP, 
DBP, and MAP percentiles in 2-week-old neonates 
born between 26 and 44 weeks of gestation. Despite 
numerous methodological limitations and the fact 
that BP is currently nearly always measured by the 
oscillometric method, reference BP values given in 
the 1987 Report of the Second Task Force are prac-
tical and easily obtainable.
Due to high rates of unreliable findings, includ-
ing false positive results (up to 41% in children 
below 12 months of age), and resulting exposure to 
unnecessary investigations and treatment, BP mea-
surement in healthy neonates is not recommended. 
Indications for BP measurement and investigations 
for hypertension are summarized in Table XXVII. 
It is recommended to perform BP measurements 
in appropriate conditions and using the technique 
described in Table XXXIX.
The incidence of hypertension in neonates is 0.2– 
–0.3%, but it is much higher among premature infants 
and in selected risk groups. Hypertension was found in 
0.81% of newborns hospitalized in neonatal intensive 
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Table XXXVII.	Reference	systolic	blood	pressure	values	
(95th	percentile)	in	neonates	(based	on	the	1987	Report	
of	the	Second	Task	Force;	reprinted	with	permission	from	
Standardy	Medyczne)
Age Reference SBP values during the first 
year of life — 95th percentile [mm Hg]
Boys Girls
≤	7	days
8–30	days
1 month
2	months
3 months
4	months
5 months
6–12	months
96
104
104
109
110
110
110
110
96
104
104
106
108
109
112
113
care units, but this rate increased to nearly 9% with 
the presence of additional risk factors (umbilical vessel 
catheterization, patent ductus arteriosus, intraventri-
cular haemorrhage) and 40% in neonates with chronic 
bronchopulmonary disease. Neonatal hypertension is 
generally of a secondary nature, related mainly to renal 
pathology, most commonly renovascular disease, but 
iatrogenic factors are also of major importance.
The approach to the differential diagnosis of hy-
pertension in neonates does not differ from that in 
older age groups. Investigations should be targeted 
at identification of hypertensive arteriolopathy, ence-
phalopathy, left ventricular hypertrophy, and kidney 
damage. These investigations are also useful when 
evaluating the effectiveness of antihypertensive the-
rapy (Table XL).
9.12.1. Treatment of neonatal hypertension
Given the lack of long-term randomized studies to 
evaluate outcomes of antihypertensive therapy in ne-
onates, most recommendations are expert opinions 
based on clinical experience. It is not recommended 
to initiate treatment in asymptomatic neonates with 
BP values between the 95th and 99th percentile. Ini-
tiation of drug treatment is justified when BP values 
are above the 99th percentile, or target organ damage 
is present with BP values above the 95th percentile. 
The general rule of drug treatment in newborns and 
infants is to choose medications depending on the 
potential aetiology of hypertension and the presence 
of concomitant abnormalities, and the treatment 
should be started with as low doses as possible. The 
safest approach is to use short-acting intravenous 
drugs (Table XLI). Oral antihypertensive therapy is 
reserved for neonates in a good overall clinical con-
dition (Table XLII).
Figure 15.	Diagnosis	of	monogenic	hypertension	based	on	the	evaluation	of	the	intermediate	phenotype.	Autosomal	dominant	brachydactyly	
with	hypertension	has	not	been	included	in	the	presented	scheme	due	to	an	unspecific	biochemical	phenotype	(normal	or	mildly	elevated	pla-
sma	renin	activity,	normal	aldosterone	level)	and	a	characteristic	clinical	phenotype	(reprinted	with	permission	from	Standardy	Medyczne)
AD,	autosomal	dominant;	AR,	autosomal	recessive;	PRA,	plasma	renin	activity
 2015 Guidelines for the Management of Hypertension
115www.nt.viamedica.pl
Table XXXVIII.	Blood	pressure	values	at	2	weeks	of	life	
in	neonates	born	between	26	and	44	weeks	of	gestation	
(based	on	Dionne	et al.,	Pediatr	Nephrol	2012)
Postconceptional age 95th percentile 99th percentile
44	weeks	of	gestations
SBP 105 110
DBP 68 73
MAP 80 85
42	weeks	of	gestation
SBP 98 102
DBP 65 70
MAP 76 81
40	weeks	of	gestation
SBP 95 100
DBP 65 70
MAP 75 80
38 weeks of gestation
SBP 92 97
DBP 65 70
MAP 74 79
36	weeks	of	gestation
SBP 87 92
DBP 65 70
MAP 72 71
34	weeks	of	gestation
SBP 85 90
DBP 55 60
MAP 65 70
32	weeks	of	gestation
SBP 83 88
DBP 55 60
MAP 62 69
30 weeks of gestation
SBP 80 85
DBP 55 60
MAP 65 68
28	weeks	of	gestation
SBP 75 80
DBP 50 54
b 58 63
26	weeks	of	gestation
SBP 72 77
DBP 50 56
MAP 57 63
DBP,	diastolic	blood	pressure;	MAP,	mean	arterial	pressure;	SBP,	systolic	blood	pressure
Table XXXIX. Technique of blood pressure measurements 
in	neonates	(based	on	Nwankwo	et al.,	Pediatrics	1997)
•	 Measurement using an oscillometric device
•	 1.5 hours after feeding or a medical intervention
•	 Child supine or prone
•	 Selection	of	an	appropriately	sized	cuff
•	 BP measurement on the right arm
•	 Earlier placement of the cuff and BP measurement after 15 minu-
tes of a quiet rest
•	 BP measurement during sleep or in a quiet awake state
•	 3	properly	performed	BP	measurements	2	minutes	apart
BP, blood pressure
Table XL. Criteria for the diagnosis of target organ damage 
in	neonates	(reprinted	with	permission	from	Standardy	
Medyczne)
Target organ damage Diagnostic criteria
Eye	fundus Grade	3/4	retinopathy
Albuminuria No reference values
Carotid	artery	IMT No	reference	values,	technically	
difficult	to	evaluate
•	 Features	of	hypertensive	car-
diomyopathy	and	aortopathy
•	 Systolic	dysfunction	without	
left ventricular enlargement
•	 Left	ventricular	hypertrophy
•	
•	 Indirect evidence of left ven-
tricular	diastolic	dysfunction	
— left atrial enlargement
•	 Enlargement of the ascending 
aorta
•	 ejection	fraction	<	60%
•	 shortening	fraction	<	29%
•	
•	
•	 left	ventricular	mass	index	 
>	47.4	±	6.2	g/m2 
•	 left atrial dimension  
>	1.89	±	0.27	cm
•	
•	 ascending aortic dimension 
>	1.04	±	2	cm
9.13. Hypertensive urgencies and emergencies
Hypertensive emergency is defined as severe hy-
pertension associated with acute target organ dam-
age and/or failure, most commonly involving the 
central nervous system, heart and/or kidneys, and 
usually presenting with Keith-Wagener-Barker grade 
3/4 retinopathy. Hypertensive urgency is defined as 
severe symptomatic hypertension without evidence 
of acute target organ damage and/or failure and with-
out Keith-Wagener-Barker grade 3/4 retinopathy. In 
the developmental period, hypertensive emergencies 
are virtually always caused by secondary hyperten-
sion, including due to acute kidney disease (acute 
glomerulonephritis, haemolytic-uremic syndrome). 
Hypertensive urgencies associated with acute BP in-
creases are also seen in children with primary hyper-
tension. The management of hypertensive urgencies 
and emergencies has been evaluated in case reports 
and case series but not in controlled clinical studies, 
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Table XLI.	Intravenous	antihypertensive	drugs	used	in	neonates	(reprinted	with	permission	from	Standardy	Medyczne)
Antihypertensive drugs Dosage Mode of administration Comments
Enalaprilat* 15	±	5	µg/kg/dose,	repeat	q	
8–24	hours
Injections	every	5–10	minutes May	result	in	long-term	hypotension	or	acute	kidney	
failure
Use limited due to these adverse effects
Esmolol 100–300	µg/kg/min Intravenous infusion Short-acting	drug,	continuous	infusion	necessary
Hydralazine* Infusion:	0.75–5.0	µg/kg/min
Bolus:	0.15–0.6	µg/kg/dose
Intravenous infusion or bolus Frequent	tachycardia;	boluses	given	every	4	hours
Labetalol* 0.2–1.0	µg/kg/dose
0.25–3.0	µg/kg/hour
Intravenous bolus or infusion Contraindications:	heart	failure,	bronchopulmonary	
dysplasia
Nicardipine 1–3	µg/kg/min Intravenous infusion May	result	in	reflex	tachycardia
Sodium nitroprusside 0.15–10	µg/kg/min Intravenous infusion Risk	of	cyanide	poisoning	if	long-term	use	or	renal	
failure
*not	available	in	Poland;	may	be	obtained	by	a	special	physician	prescription
Table XLII.	Oral	antihypertensive	drugs	used	in	neonates	(reprinted	with	permission	from	Standardy	Medyczne)
Antihypertensive drugs Dosage Mode of administration Comments
Captopril <	6	months:	0.01–0.5	mg/
kg/dose
Maximum	6	mg/kg/day
3	×	day Drug of choice in most neonates
Need to monitor potassium and creatinine level
Clonidine 0.05–0.1	mg/kg/dose 2–3	×	day Causes	dry	mouth	and	somnolence
Rebound	hypertension	if	stopped	abruptly
Hydralazine* 0.25–1.0	mg/kg/dose
Maximum	7.5	mg/kg/day
3–4	×	day Tachycardia	and	fluid	retention	are	frequent	adverse	effects
Isradipine 0.05–0.15	mg/kg/dose
Maximum	0.8	mg/kg/day
4	×	day Effective	in	acute	and	chronic	hypertension
Amlodipine 0.1–0.3	mg/kg/dose
Maximum	0.6	mg/kg/day
2	×	day Hypotension	less	frequent	than	with	isradipine
Propranolol 0.5–1.0	mg/kg/dose 3	×	day Maximum	dose	depends	on	heart	rate:	if	bradycardia	is	not	
present,	the	dose	may	be	increased	to	8–10	mg/kg/day
Contraindicated	in	bronchopulmonary	dysplasia
Labetalol* 1.0	mg/kg/dose
Maximum	10	mg/kg/day
2–3	×	day Contraindicated	in	bronchopulmonary	dysplasia
Need to monitor heart rate
Spironolactone 0.5–1.5	mg/kg/dose 2	×	day Results in potassium retention — need to monitor elec-
trolytes
Full	effect	seen	after	several	days
Hydrochlorothiazide 1–3	mg/kg/dose 4	×	day Need	to	monitor	electrolytes
*not	available	in	Poland;	may	be	obtained	by	a	special	physician	prescription
and recommendations presented in the guidelines 
(2009 ESH guidelines and the 2004 fourth report 
of the National High Blood Pressure Education Pro-
gram Working Group on Children and Adolescents) 
are based on expert opinion. It is recommended to 
treat hypertensive emergencies in an intensive care 
unit, with intravenous line access and ECG, BP, 
respiratory function (pulse oximetry), and fluid bal-
ance monitoring. Blood pressure should be measured 
every 15 minutes until it is reduced by 30% of the 
overall target BP reduction. In addition to fundosco-
py, biochemical blood testing including renal func-
tion, electrolytes, and venous blood gases is recom-
mended in all patients with hypertensive urgencies 
and emergencies, and if the aetiology of hypertension 
is not known, an initial differential diagnosis should 
also be performed including renal ultrasound with 
Doppler evaluation of the renal arteries and echo-
cardiography to evaluate LVM. During subsequent 
hours of treatment, BP may be measured every 30– 
–60 minutes depending on the clinical condition of 
the patient. The general approach to the treatment of 
a hypertensive emergency in children and adolescents 
is based on gradual, controlled BP reduction. It is 
recommended to lower BP by 25–30% of the overall 
target BP reduction within 6–8 hours and by another 
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Figure 16.	Management	of	hypertensive	urgencies	and	emergencies.	Reprinted	with	permission	from	Standardy	Medyczne
30% within the next 24–36 hours. Normal BP values 
(< 90th to 95th percentile) should be reached within 
72–96 hours. Intravenous medications are used for 
the treatment of hypertensive emergencies, with the 
choice of the drug based on the aetiology of hyper-
tension. In hypertensive emergencies, administration 
of an intravenous beta-blocker (labetalol, esmolol) 
and a peripheral vasodilating agent (hydralazine, 
sodium nitroprusside, or nitroglycerin) is recom-
mended. Due to fluid retention caused by peripheral 
vasodilation during prolonged therapy, an addition 
of a diuretic is also recommended. Oral treatment is 
initiated upon improvement of the general clinical 
condition of the patient. In hypertensive crises due to 
acute or chronic kidney disease (patients on dialysis 
therapy), volume control and removal of excess fluid 
by dialysis, or using diuretics in patients with pre-
served glomerular filtration, is of major importance. 
Addition of a RAAS inhibitor is recommended in 
hypertensive emergencies due to microangiopathy.
In hypertensive urgencies, oral treatment is usually 
possible. BP should lowered by 30% of the overall 
target BP reduction within the first 6 hours, and 
target BP values should be gradually reached during 
the next 36–48 hours. The management approach 
is shown in Figure 16, and dosage of the drugs used 
in hypertensive emergencies, along with their ad-
verse effects and contraindications, is summarized in 
Table XLIII. In children with hypertensive urgencies 
and acute BP rises who may be treated with oral 
medications, rapidly acting drugs are recommended, 
followed by the institution of long-term antihyper-
tensive therapy (Table XLIV).
Drug dosage for long-term antihypertensive thera-
py in children is summarized in Table XLV.
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Table XLIII.	Antihypertensive	drugs	used	in	hypertensive	emergencies	(reprinted	with	permission	from	Standardy	Medyczne)
Antihypertensive 
drugs
Dosage Mode of 
administration
Comments
Nicardipine* Bolus:
30	µg/kg	up	to	a	maximum	
dose	of	2	mg
Infusion:
0.5–4	µg/kg/min
Intravenous bolus or 
infusion
May	induce	reflex	tachycardia
Labetalol* Bolus:
0.2–1	µg/kg	up	to	a	maxi-
mum	dose	of	40	mg
Infusion:
0.25–3	µg/kg/hour
Intravenous bolus or 
infusion
Contraindications: asthma, heart failure, diabetes
May	result	in	hyperkalaemia	and	hypoglycaemia
Does	not	induce	reflex	tachycardia
Hydralazine* Bolus:
0.2–0.6	µg/kg	up	to	a	maxi-
mum	dose	of	20	mg
Intravenous or intra-
muscular bolus
Often	reflex	tachycardia,	fluid	retention,	headaches
Intravenous	boluses	should	be	given	every	4	hours
Esmolol Infusion:
100–500	µg/kg/min,	up	to	
1000	µg/kg/min
Intravenous infusion May	result	in	bradycardia
Contraindications: asthma, heart failure
Very	short	duration	of	action
Enalaprilat* Bolus:
5–10	µg/kg	up	to	a	maxi-
mum	dose	of	1.2	mg
Intravenous bolus May	result	in	long-lasting	hypotension,	hyperkalaemia	or	acute	
renal failure
Limited indications
Fenoldopam* Infusion:
0.2–0.8	µg/kg/min
Intravenous infusion Little	experience	in	children
Sodium nitroprusside* Infusion:
0.5–10	µg/kg/min
Intravenous infusion Risk	of	cyanide	poisoning	if	long-term	use	or	concomitant	renal	
or hepatic failure
Need	to	monitor	cyanide	levels	during	long-term	use	(>	48	
hours)
Phentolamine* Bolus:
0.05–0.1	mg/kg	up	to	a	ma-
ximum	dose	of	5	mg
Intravenous bolus May	result	in	tachycardia
Drug of choice in an adrenergic crisis
Clevidipine* Infusion:
0.5–3.5	µg/kg/min
Intravenous infusion Contraindications:	allergy	to	soybean	and	egg	proteins,	dyslip-
idaemia
Few	data	regarding	paediatric	dosage
*not	available	in	Poland;	may	be	obtained	by	a	special	physician	prescription
Table XLIV.	Oral	antihypertensive	drugs	used	in	hypertensive	urgencies	(reprinted	with	permission	from	Standardy	Medyczne)
Antihypertensive 
drugs
Dosage Mode of 
administration
Comments
Captopril 0.3–0.5	mg/kg/dose
Maximum	6	mg/kg/day
Oral Need to monitor potassium and creatinine level
Clonidine 0.05–0.1	mg/dose,	may	be	repeated	up	to	a	maximum	
dose of 0.8 mg
Oral Adverse	effects:	dry	mouth,	sedation
Isradipine 0.05–0/1	mg/kg/dose,	up	to	a	maximum	dose	of	5	mg Oral Adverse	effects:	dizziness,	reflex	tachycardia
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Table XLV.	Recommended	doses	of	oral	antihypertensive	drugs	in	children
Drug class Drug Initial dose Number of 
daily doses
Maximum dose
Aldosterone anta-
gonists
Eplerenone* 25–50	mg/day 1–2 100	mg/day
Spironolactone 1	mg/kg/day 1–2 3.3	mg/kg/day	up	to	100	mg/day
Angiotensin-conver-
ting	enzyme	inhibitors
Benazepril* 0.2	mg/kg/day	up	to	10	mg/day 1 0.6	mg/kg/day	up	to	40	mg/day
Captopril 0.3–0.5	mg/kg/dose 2–3 6	mg/kg/day	up	to	450	mg/day
Enalapril* 0.08	mg/kg/day 1–2 0.6	mg/kg/day	up	to	40	mg/day
Fosinopril* 0.1	mg/kg/day	or	5–10	mg/day 1 0.6	mg/kg/day	up	to	40	mg/day
Lisinopril* 0.07	mg/kg/day	up	to	5	mg/day 1 0.6	mg/kg/day	up	to	40	mg/day
Quinapril* 5–10	mg/day 1 80	mg/day
Ramipril 2.5	mg/day	(6	mg/m2/day) 1 20	mg/day
Angiotensin receptor 
blockers
Candesartan* 0.16	mg/kg/day	up	to	4	mg/day 1 0.5	mg/kg/day	up	to	32	mg/day
Irbesartan* <	13	years:	75–150	mg/day
>	13	years:	150–300	mg/day
1 300	mg/day
Losartan* 0.75	mg/kg/day	up	to	50	mg/day 1 1.44	mg/kg/day	up	to	100	mg/day
Valsartan* 0.25–2	mg/kg/day 1 4	mg/kg/day	up	to	320	mg/day
Olmesartan* 2.5	mg/day 1 40	mg/day
Renin inhibitors Aliskiren 2	mg/kg/day 1 6	mg/kg/day	up	to	600	mg/day
Alpha- and be-
ta-blockers
Labetalol** 1–3	mg/kg/day 2 10–12	mg/kg/day	up	to	1.2	g/day
Carvedilol 0.1	mg/kg/dose	up	to	12.5	mg/
dose
2 0.5	mg/kg/dose	up	to	50	mg/day
Beta-blockers Atenolol 0.5–1	mg/kg/day 1–2 2	mg/kg/day	up	to	100	mg/day
Bisoprolol/	hydrochlorothia-
zide**
0.04	mg/kg/day	up	to	2.5/6.25	
mg/day
1 10/6.25	mg/day
Metoprolol* 0.5–1.0	mg/kg/day	up	to	50	mg/
day
1–2 6	mg/kg/day	up	to	200	mg/day
Propranolol 1	mg/kg/day 2–3 16	mg/kg/day	up	to	640	mg/day
Calcium antagonists Amlodipine* 0.06	mg/kg/day	or	2.5–5	mg/day 1 0.6	mg/kg/day	up	to	10	mg/day
Felodipine* 2.5	mg/day 1 10	mg/day
Isradipine 0.05–0.15	mg/kg/day 3–4 0.8	mg/kg/day	up	to	20	mg/day
Nifedipine	(slow	release) 0.25–0.5	mg/kg/day 1–2 3	mg/kg/day	up	to	120	mg/day
Central alpha-ago-
nists
Clonidine 5–10	µg/kg/day 2–3 25	µg/kg/day	up	to	0.9	mg/day
Methyldopa 5	mg/kg/day 2–3 40	mg/kg/day	up	to	3	g/day
Diuretics Amiloride 0.4	mg/kg/day	or	5–10	mg/day 1 0.625	mg/kg/day	up	to	20	mg/day
Chlorthalidone 0.3	mg/kg/day 1 2	mg/kg/day	up	to	50	mg/day
Furosemide 0.5–2.0	mg/kg/dose 1–2 6	mg/kg/day	up	to	450	mg/day
Hydrochlothiazide 0.5–1	mg/kg/day 1 3	mg/kg/day	up	to	50	mg/day
Alpha-blockers Doxazosin 1	mg/day 1 4	mg/day
Prazosin 0.05–0.1	mg/kg/day 3 0.5	mg/kg/day	up	to	50	mg/day
Terazosin 1	mg/day 1 20	mg/day
Vasodilators Hydralazine** 0.25	mg/kg/dose 3–4 7.5	mg/kg/day	up	to	200	mg/day
*approved	by	the	FDA	for	the	treatment	of	hypertension	in	children 
**not	available	in	Poland;	may	be	obtained	by	a	special	physician	prescription
